We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cellzome Announces Achievement of Second Milestone in Epigenetics Collaboration with GSK
News

Cellzome Announces Achievement of Second Milestone in Epigenetics Collaboration with GSK

Cellzome Announces Achievement of Second Milestone in Epigenetics Collaboration with GSK
News

Cellzome Announces Achievement of Second Milestone in Epigenetics Collaboration with GSK

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cellzome Announces Achievement of Second Milestone in Epigenetics Collaboration with GSK"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cellzome has announced that it has achieved the second milestone in its epigenetics alliance with GlaxoSmithKline. The milestone triggers a payment of an undisclosed amount from GSK and follows only two months after the first milestone was achieved.

The strategic collaboration in epigenetics was announced in March 2010 and gives GSK exclusive access to Cellzome’s proprietary Episphere™ technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Under the terms of the agreement, the companies work together using Cellzome’s Episphere™ technology platform, to identify selective small-molecule drug candidates against targets from four different epigenetic target classes.

The companies share operational responsibility for the programs until identification of drug candidates, at which stage GSK will assume responsibility for any further preclinical and clinical development and commercialization.

Tim Edwards, CEO of Cellzome, said: “Achieving the second milestone in this collaboration in less than a year after its start demonstrates how well our technology is suited to address drug discovery for epigenetic targets. It also shows how well the scientists from Cellzome and GSK work together.”

Cellzome is eligible for milestone payments and tiered royalties for each programme in this epigenetic collaboration with GSK. Milestone payments over the course of the collaboration could reach over €475 million if all programmes under the alliance are successfully developed and commercialized.

Advertisement